With transdermal therapeutic system (TTS) and oral thin films (OTF), LTS has created several innovative drug delivery systems. We combine your active substances with cutting-edge applications that make patients’ lives easier. This is why alternative delivery systems such as LTS-TTS and LTS-OTF should also be taken into account.
In clinical trials in particular, active substances frequently fail as a result of the fact that tablets, capsules or solutions cannot be applied for various reasons, or because they do not accomplish the necessary bioavailability.
Trials often reach phase II before it is discovered that the delivery system cannot achieve the therapy success envisaged. At this point many trials are terminated and consigned to the back of a filing cabinet. Promising active substances are then no longer accessible for the patient.
It is at this point at the very latest that researchers should also consider alternative delivery systems, and this is where transdermal therapeutic system (TTS) and oral thin films (OTF) can open up a whole new range of opportunities.